Herzuma Purple Book BLA 761091

BLA number
761091
Proprietary names
Herzuma
Proper names
trastuzumab-pkrb
Applicant
CELLTRION, Inc.
Center
CDER
First observed release
2020-02-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Herzumatrastuzumab-pkrb351(k) Biosimilar420MGFor InjectionIntravenousMulti-Dose VialRxLicensed2018-12-14
002Herzumatrastuzumab-pkrb351(k) Biosimilar150MGFor injectionIntravenousSingle-Dose VialRxLicensed2019-05-16

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
103792Herceptintrastuzumab351(a)Disc*2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-07-01U001Herzuma351(k) BiosimilarRxCELLTRION, Inc.
2021-07-01U002Herzuma351(k) BiosimilarRxCELLTRION, Inc.
2021-05-01U001Herzuma351(k) BiosimilarRxCelltrion
2021-05-01U002Herzuma351(k) BiosimilarRxCelltrion

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Herzuma351(k) BiosimilarRxLicensed2018-12-14
2020-05-01002Herzuma351(k) BiosimilarRxLicensed2019-05-16
2020-02-01001Herzuma351(k) BiosimilarMarketedLicensed2018-12-14
2020-02-01002Herzuma351(k) BiosimilarMarketedLicensed2019-05-16